Zhou Zhifeng, Managing Partner of Qiming Venture Partners, was honored as one of the world's best venture capitalists on the Forbes Midas List 2026.
On May 27, 2026, Forbes officially released the 2026 Global Midas List. Zhou Zhifeng, a managing partner of Qiming Venture Partners, made his debut on the list as a Chinese technology, especially AI, investor, ranking 80th.
The Midas List, known as the "Oscars of the investment world," is the most influential list of investors in the global venture capital industry. This year marks the 25th anniversary of the list's establishment, and the competition is particularly fierce - the soaring valuations of SpaceX, OpenAI, and Anthropic have brought 25 new investors onto the list.
Zhou Zhifeng, Managing Partner of Qiming Venture Partners
Zhou Zhifeng joined Qiming Venture Partners in 2014 and was promoted to managing partner in May 2024. He has over 20 years of combined experience in industry, entrepreneurship, and investment, and has long been focused on the cutting - edge technology field. He is one of the most active investors in transformative technology fields such as artificial intelligence and robotics.
Since the beginning of 2026, within just five months, four companies invested by Zhou Zhifeng, namely Biren Technology, Zhipu, Aixin Yuanzhi, and Yunyinggu Technology, have successively gone public.
In the field of technology, especially AI investment, Zhou Zhifeng always adheres to the methodology of "being half a step ahead" - in some fields where he has established his "circle of competence," he keenly captures key industrial signals, anticipates trends, and makes early layouts, rather than following the trend when the market boom arrives. He believes that in the face of paradigm - shifting waves, this is the optimal investment method to achieve excess returns.
At the end of 2019, when there were few participants in the domestic GPU track and the demand for AI computing power was not yet recognized by the mainstream, Zhou Zhifeng, as a founding investor, proactively entered the market when Biren Technology was founded. He led the first - round financing and continued to increase his investment, supporting it all the way to become the first GPU stock on the Hong Kong Stock Exchange.
At the beginning of 2022, when the development prospects of artificial intelligence were still unclear, the concept of large models had not been proposed in the market, and even few investors had noticed the signals of technological change, Zhou Zhifeng invested in Zhipu. That round of funding supported Zhipu to develop the first - generation GLM model.
In the field of embodied intelligence, in addition to investing in Ubtech Robotics 11 years ago, Zhou Zhifeng led his team to invest in full - stack companies integrating models and entities, such as Tashizhihang, Yuanlilingji, Yinhe Tongyong, and Daxiao Robotics, in the early stage of the new round of development in recent years.
Qiming Venture Partners was founded in 2006. Now it manages 11 US dollar funds and 7 RMB funds, with an asset management scale of 9.5 billion US dollars. Since its establishment, Qiming Venture Partners has always focused on two core sectors: technology and medical innovation, forming a unique "dual - wheel drive" pattern.
In the technology field, Qiming Venture Partners has been deeply involved in the AI field for more than a decade - since 2013, it has been laying out in deep learning, with a cumulative investment of over 100 AI projects and a total investment of 12 billion RMB. The invested companies cover the entire AI industry chain. It is one of the most active and influential investment institutions in the field of artificial intelligence in China and even Asia. From large models to multimodality and then to embodied intelligence, Qiming Venture Partners' investment decisions have always been based on the technology development curve, rather than blindly chasing short - term hotspots in the capital market.
In the field of medical innovation, Qiming Venture Partners is one of the first teams in China to comprehensively enter this field for venture capital investment. In the past two decades, Qiming Venture Partners' medical innovation team has invested in nearly 200 companies. Currently, it focuses on innovative drugs, innovative medical devices, and AI medical applications. Qiming Venture Partners' in - depth involvement in this field has not only promoted the innovative development of China's medical and health industry but also brought tangible clinical value to global patients.
The two sectors empower each other. The industrial knowledge accumulated by Qiming Venture Partners in the medical innovation field provides unique insights for the investment in AI medical applications; while the cutting - edge technology judgment in the technology sector also empowers the medical team to identify technology - driven companies with disruptive potential. This cross - sectoral synergy is Qiming Venture Partners' systematic advantage.
On the Midas List, the world's highest - level list of investors, from technology to medical innovation and then to artificial intelligence, Qiming Venture Partners' investors have continuously gained global recognition in different years and fields. At the core is the systematic ability formed by Qiming Venture Partners in nearly two decades: long - term focus on the two core sectors, systematic layout of "being half a step ahead," and full - chain professional ability covering the early stage to the growth stage.
Whether in the field of technology or medical innovation, Qiming Venture Partners has started systematic layout several years before the market consensus is formed, accompanied the growth of enterprises with a long - term perspective, and finally achieved a good harvest at the exit stage.
Kuang Ziping, the founding managing partner of Qiming Venture Partners, once made this judgment: "In the next twenty years, investing in AI is the greatest certainty in Chinese investment." Now, this judgment is being verified by the positive cycle of the team in fundraising, investment, management, and exit.